secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000950170-24-118573
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance
---------------------------------------------------------

- Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.
- FY2024 constant currency revenue growth guidance narrowed to 4.25%-4.75% from 5.0%-6.0%.
- FY2024 adjusted diluted EPS guidance lowered to $7.95-$8.05 from $8.00-$8.15.
- CEO Ivan Tornos cited ERP implementation challenges as headwind to full-year performance.
- Completed acquisition of OrthoGrid Systems (AI hip guidance); launched Z1 Femoral Hip System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024118573/0000950170-24-118573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017024118573/zbh-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-118573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer